STAT+: Eli Lilly to buy three small vaccine developers
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Curevo will be acquired by Eli Lilly, announced on Tuesday.
- LimmaTech Biologics will be acquired by Eli Lilly, announced on Tuesday.
- Vaccine Company will be acquired by Eli Lilly, announced on Tuesday.
- The three deals together could cost up to nearly $4 billion.
- Lilly’s recent purchases have focused on cancer, autoimmune diseases, and sleep disorders, each for under $10 billion.
Why it matters: Lilly gains a foothold in the vaccine market, accelerating its diversification while vaccine developers secure funding; competitors feel pressure as Lilly’s cash‑rich expansion reshapes the biotech M&A landscape.
